Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

NCT01410513 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: SAR245409

Sponsor

Sanofi